Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of SYH2070 injection in Chinese adults with homozygous familial hypercholesterolemia
CTR20261813Phase 2Active
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Jun 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SYH2070 in homozygous familial hypercholesterolemia (HoFH), sponsored by CSPC Zhongnuo Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
SYH2070
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on CTR20261813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261813.